Condition: Heart Failure · Sponsor: Chengdu Suncadia Medicine Co., Ltd.
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.
This description comes directly from the study's public registry record.
Hui Xu · +86 0518-82342973 · hui.xu.hx107@hengrui.com
Chang Shu · +86-0518-82342973 · chang.shu@hengrui.com
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07551167